icines that can make a difference to patients. We are one of the pharmaceutical industry leaders, with an estimated seven per cent of the world's pharmaceutical market and one of the few companies researching both medicines and vaccines for the World Health Organization's three priority diseases - HIV/AIDS, tuberculosis and malaria. As a company with a firm foundation in science, we have a flair for research and a track record of turning that research into powerful, marketable drugs.
About the Wellcome Trust
The Wellcome Trust is a global charitable foundation dedicated to achieving extraordinary improvements in human and animal health. It supports the brightest minds in biomedical research and the medical humanities. The Trust's breadth of support includes public engagement, education and the application of research to improve health. It is independent of both political and commercial interests. http://www.wellcome.ac.uk
About the Department for Business, Innovation and Skills
The Department for Business, Innovation and Skills (BIS) is building a dynamic and competitive UK economy by: creating the conditions for business success; promoting innovation, enterprise and science; and giving everyone the skills and opportunities to succeed. To achieve this it will foster world-class universities and promote an open global economy. BIS - Investing in our future.
About the Technology Strategy Board
The Technology Strategy Board works to drive economic growth by making the UK a global leader in innovation. Established by the government, the Technology Strategy Board helps business to innovate faster and more effectively than would otherwise be possible. It uses its expertise, connections and funding to enable collaborations and partnerships between businesses, researchers and government, and to help business to create innovative products and services which will meet market needs, tackle the ch
Page: 1 2 3 4 5 Related biology technology :1
|SOURCE Stevenage Bioscience Catalyst|
Copyright©2012 PR Newswire.
All rights reserved
. Stevenage Bioscience Catalyst Opens With Exciting Year Ahead2
. Fitzsimons Redevelopment Authority Rolls Out First Phase of Strategic Refocus With Appointment of Four Key Leaders in The Bioscience Industry to Its Board of Directors3
. Ambit Biosciences Names Michael A. Martino President and Chief Executive Officer4
. Kansas Bioscience Authority Announces FY11 Outcomes of $207 Million5
. The Law Firm of Levi & Korsinsky, LLP Launches an Investigation Into Possible Securities Laws Violations by Pacific Biosciences of California, Inc.6
. Coronado Biosciences to Present at the Oppenheimer 22nd Annual Healthcare Conference7
. Coronado Biosciences Announces Phase 1 Results of CNDO-109 in AML to be Presented at the American Society of Hematology8
. Sangamo BioSciences Announces Presentation of New Data from ZFP Therapeutic® Program in Hemophilia B at American Society for Hematology Meeting9
. Ohios Bioscience Industry Effort Paying Off With Increase in Graduates and Accolades for the State10
. Sangamo BioSciences Announces Presentation at J.P. Morgan Healthcare Conference11
. Roka Bioscience Secures $47.5 Million in Series D Financing